

Compound (VI f) Dose-Dependently Suppresses TNF Release from RAW Cells FIG. 1



Concentration, uM

Compound (VI.f) Dose-Dependently Suppresses FIG. 2



2/6

FIG. 3 IC₅₀ values for TNF Inhibition in RAW Cells


IC_{50} (μM)	7		~	~	~	> 10	> 100
Compound	Nicotine	VI f	VIb	XII b	VI e	VI g	XII a

4/6

Compound (VI f) is Protective in the Mouse CLP Model of Septic Shock

	Carrier	Compound (VI f)
Day-1	13	13
Day 0	13	13
Day 1	6	12
Day 2	6	12
Day 3	6	12
Day 4	6	12
Day 5	L	12
Day 6	7	12
Day 7	7	12
Day 8	L	11
Day 9	7	11
Day 10		11
Day 11	7	11
Day 12	7	11
Day 13	7	11
		AND THE PARTY OF T

Injection of Compund (VI f) or Carrier, b.l.d. /what is b.l.d.?/



human macrophages by Compounds VI d and VI f and Nicotine Inhibition of TNF production from LPS-stimulated FIG. 5

6/6

FIG. 6 Does α -Bungarotoxin override Compound (VI f) inhibitory effect?

